All PlansAdministrativeMedium impact
Voluntary nationwide recall: Cetirizine (Unique – July)
UPMC Health Plan·Pharmacy·Pharmacy
Effective date
Jul 20, 2026
We identified it
Aug 7, 2026
Summary
Unique Pharmaceutical Laboratories is recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg due to cross-contamination with Ranitidine. Affected lots (GY825029, GY825030, GY825031, GY825032) contain red dots on tablets and pose risk of severe allergic reactions. The billing team must alert patients and providers to verify medication lot numbers and stop use of affected inventory immediately.
Action Required
Immediately: Pharmacy and clinical staff must identify and quarantine all Cetirizine Hydrochloride Tablets USP 5 mg in inventory matching lot numbers GY825029, GY825030, GY825031, or GY825032. Billing team must: (1) Flag any recent claims for these cetirizine lots for potential reversal or adjustment if patients request refunds; (2) Notify patients who filled prescriptions from affected lots to contact their pharmacy or doctor; (3) Update patient records to document recall communication. Contact Rising Pharma Holdings Inc. at 844-874-7464 (Monday-Friday, 8 a.m.–5 p.m. EST) or visit FDA website for additional guidance. No adverse events reported as of July 20, 2026, but immediate action prevents potential claims related to adverse reactions.